PharmiWeb.com - Global Pharma News & Resources
28-Jul-2005

Taishi's 20-HETE synthesis inhibitor, TS-011 as a candidate acute treatment for hemorrhagic and ishemic stroke

Taishi's 20-HETE synthesis inhibitor, TS-011 as a candidate acute treatment for hemorrhagic and ishemic stroke

Summary

Each year, 750,000 strokes occur in the US and resultant deaths account for stroke being one of the top three causes of mortality as well as a major economic burden on healthcare systems. One candidate molecular target for stroke is 20-HETE. Taisho Pharmaceutical have developed a potent and selective 20-HETE synthesis inhibitor, TS-011 for the treatment of stroke.
Last Updated: 27-Aug-2010

Each year, 750,000 strokes occur in the US and resultant deaths account for stroke being one of the top three causes of mortality as well as a major economic burden on healthcare systems (see Acute Stroke - Symptom Awareness Will Reduce Headache). Most strokes are ischemic however 20% are hemorrhagic; irrespective of the subtype treatments are limited. One candidate molecular target for stroke is 20-HETE, an ecosanoid that has been suggested to contribute to the development of vasospasm. Taisho Pharmaceutical have developed a potent and selective 20-HETE synthesis inhibitor, TS-011 which has been reported to display efficacy in models of both hemorrhagic and ischemic stroke. The latest available new from Taisho is that TS-011 entered phase I development in the US in 2003...[more]

Source LeadDiscovery